✨ Free AI Report
Intensity Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Intensity Therapeutics, Inc.
Company Research

Intensity Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Intensity Therapeutics, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Biotech stock in pivotal Phase 3 trial with promising immune activation data, but facing near-term delisting risk and significant execution risk on clinical endpoints. The company received a 180-day Nasdaq extension to regain compliance with the minimum $1.00 bid price requirement, reflecting liquidity pressures. However, analyst price targets average.

What is Intensity Therapeutics, Inc.'s industry? Intensity Therapeutics, Inc. (intensitytherapeutics.com) operates in Biotechnology - Oncology/Cancer Therapeutics. AskCyborg classifies Intensity Therapeutics, Inc. under Biotechnology - Oncology/Cancer Therapeutics in its company registry.

Intensity Therapeutics is a late-stage clinical biotechnology company developing treatments for regional and systemic cancer, with its lead product INT230-6 in Phase 3 studies for soft tissue sarcoma and Phase 2 trial...

5/ 10Mixed

Cyborg Score thesis

Biotech stock in pivotal Phase 3 trial with promising immune activation data, but facing near-term delisting risk and significant...

Read the full analyst-debate transcript →
Industry Biotechnology - Oncology/Cancer Therapeutics
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Intensity Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Intensity Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Intensity Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Intensity Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Intensity Therapeutics, Inc. Overview

Pro stress-test →

Intensity Therapeutics is a late-stage clinical biotechnology company developing treatments for regional and systemic cancer, with its lead product INT230-6 in Phase 3 studies for soft tissue sarcoma and Phase 2 trials for triple negative breast cancer. The company's DfuseRx platform involves direct tumor injection of a unique combination of cisplatin, vinblastine, and an amphiphilic molecule.

Strategic Profile

Pro stress-test →

Intensity's clinical data demonstrates abscopal effects (shrinkage of uninjected tumors) and increased immune activation, suggesting systemic immune engagement following local tumor destruction. The company has successfully extended cash runway and is executing pivotal late-stage trials, positioning itself for potential regulatory milestones in 2026-2027.

Competitive Landscape

Pro stress-test →

Competitors in clinical-stage cancer therapeutics include Theriva Biologics and Plus Therapeutics. Intensity's differentiation centers on its localized injection approach with systemic immune activation, targeting underserved cancer indications with limited alternatives.

Industry Context

Intensity Therapeutics, Inc. operates in Biotechnology - Oncology/Cancer Therapeutics.

Key facts

Founded: 2012 · Headquarters: Shelton, Connecticut · Market cap: $19.3M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Intensity Therapeutics, Inc..

  • Q1 2026 protocol amendment planned to revise INT230-6 dosing in the INVINCIBLE-4 breast cancer trial
  • Cash runway extends into Q2 2027, indicating near-term funding requirement
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 20261-for-25 reverse stock split approved to address minimum price compliance
  • January 2026Strategic priorities outlined with extended cash runway into H2 2026
  • +1 moreTrack every material event for Intensity Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Intensity Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Immunotherapy PlatformClinical-stage immunotherapy company→Cancer Therapeutics PlatformPrecision cancer medicine developer→

Compare Intensity Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Intensity Therapeutics, Inc. operates in Biotechnology - Oncology/Cancer Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Oncology/Cancer Therapeutics research →
NEW · MCP server

Ask your AI assistant about Intensity Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Intensity Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Intensity Therapeutics, Inc. do this quarter?”
“Is Intensity Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Intensity Therapeutics, Inc. do?+
Intensity Therapeutics is a late-stage clinical biotechnology company developing treatments for regional and systemic cancer, with its lead product INT230-6 in Phase 3 studies for soft tissue sarcoma and Phase 2 trial...
What is Intensity Therapeutics, Inc.'s Cyborg Score?+
Intensity Therapeutics, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Intensity Therapeutics, Inc.'s main competitors?+
Named competitors include Immunotherapy Platform, Cancer Therapeutics Platform. The full competitive landscape is in the AskCyborg report.
How can I get the full Intensity Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Intensity Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Intensity Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Replimune Group, Inc.3Alligator Bioscience AB3Elevation Oncology, Inc.